Immune checkpoint inhibitorsOesophageal cancerCheckMate 577KEYNOTE-590Oesophageal squamous cell carcinoma (ESCC)ESCC
…t advances, the 5-year survival rate remains modest at 10%–30%. Immune checkpoint inhibitors, exemplified by KEYNOTE-590 and CheckMate 577 trials, have resh…